QLT Inc. (QLTI) announced the Board of Directors has decided to implement several new initiatives designed to enhance shareholder value. These initiatives include the sale of QLT USA, Inc. whose primary assets include the Eligard(R) product line for prostate cancer, Aczone(TM), a dermatology product for the treatment of acne vulgaris, and the Atrigel(R) drug delivery system, either in a single transaction or series of transactions. The Company also plans to sell the land and building associated with and surrounding the corporate headquarters in Vancouver. The Company will also implement a reduction in headcount of 115 employees with planned future reductions as assets are divested.
KNOBIAS DISCLAIMER: All statements made in this article were made by the Company and do not in any way reflect the opinions of Knobias. Knobias is not a registered broker-dealer, nor investment advisor, and does not endorse or recommend any securities mentioned. This story is provided for informational purposes only and is not intended for trading purposes. Knobias shall not be liable for any actions taken in reliance of any information provided herein. Republication or redistribution of Knobias content is expressly prohibited without prior written consent of Knobias.com, LLC.
ABOUT KNOBIAS: Knobias is a premier financial information provider of trading and investing data covering all U.S. equities for investors and security professionals. Knobias is best described by its three major components: Real-time desktop applications providing quotes, charts, level 2, analysis etc.; Knobias RAiDAR providing thousands of real-time news stories, alerts and documents daily; Knobias fundamentals providing a comprehensive database of fundamental research information.
If your company wishes to participate in the EventX newswire, please contact Knobias: http://www.knobias.com
Knobias.com, LLC 601-978-3399 601-978-3675 info@knobias.com www.knobias.com/cmtx
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
|
|
